Abstract
The need for routine prolactin (PRL) measurement in the initial evaluation of erectile dysfunction (ED) has been questioned because of the low rate of hyperprolactinemia (HP) in these men and the costs involved. In addition, it is widely thought that sexual desire problems are a good clinical marker for HP and/or low testosterone in men with ED. Within a 15-month period, 844 consecutive PRL and sexual hormone determinations were conducted in men at the Kingston General Hospital. Of these patients, 138 were comprehensively evaluated at the first visit for ED and completed the International Index of Erectile Function (IIEF). In the 138 patients, 2.2% had severe hyperprolactinemia (>35 ng/ml), within the range of 1–5% previously reported. No correlation between initial prolactin value and the sexual desire domain or the erectile function domain (EFD) of the IIEF was found for this population. However, all cases of severe HP were found to occur in men who scored less than 10 in the EFD of the IIEF. Low libido is widely accepted as a marker of HP. In this study, HP was found in patients not reporting major problems with a desire disorder. Clinically significant HP may be reliably found with routine biochemical evaluation and in this series was not detected in patients with EFD scores above 10. A routine PRL measurement is inexpensive and early detection of a serious and treatable disease may afford greater therapeutic success.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akpunonu BE et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 1994 9, 336–338.
Buvat J, Lemaire A. . Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997 158, 1764–1767.
Nickel JC et al. Endocrine dysfunction in impotence: incidence, significance, and cost-effective screening. J Urol 1984 132, 40–43.
Seftel AD. . Editorial: erectile dysfunction—the paradigm changes but the challenges remain. J Urol 1997 156, 1768–1769.
Garg RK, Khaishgi A, Dandona P. . Is management with sildenafil changing clinical practice? Lancet 1999 353, 375–376.
Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dyfunction. Urology 1997 49, 822–830.
Padma-Nathan H. . Diagnostic and treatment strategies for erectile dysfunction: the ‘Process of Care’ model. Int J Impot Res 2000 12(Suppl 4), S119–S121.
NIH Consensus Development Panel on Impotence. . Impotence. JAMA 1993 270, 83–90.
Johnson AR, Jarow JP. . Is routine endocrine testing of impotent men necessary? J Urol 1992 147, 1542–1544.
Foster RS et al. Role of serum prolactin determination in evaluation of impotent patient. Urology 1990 XXXV1, 499–501.
Cappelleri JC et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999 54, 346–349.
Sinha YN. . Structural variants of prolactin: occurrence and physiological significance. Endocrine Rev 1995 16, 354–369.
Leite V et al. Characterization of big–big prolactin in patients with hyperprolactinemia. Clin Endocrinol 1992 37, 365–372.
Guay AT, Sabharwal P, Varma S, Malarkey WB. . Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 1996 81, 2512–2514.
Tritos NA, Guay AT, Malarkey WB. . Asymptomatic ‘big’ hyperprolactinemia in two men with pituitary adenomas. Eur J Endocrinol 1998 138, 82–85.
Cavaco B et al. Hyperprolactinemia due to big–big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999 22, 203–208.
Kropman RF et al. Routine endocrine screening in impotence: significance and cost-effectiveness. Int J Impot Res 1991 3, 87.
Maatman TJ, Montague DK. . Routine endocrine screening in impotence. Urology 1986 27, 499.
Leonard MP, Nickel CJ, Morales A. . Hyperprolactinemia and impotence: why, when, and how to investigate. J Urol 1989 142, 992.
Zonszein J. . Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin N Am 1995 22, 789–802.
Besser GM et al. Clinical and therapeutic aspects of hyperprolactinemia. In: MacLeod RM, Thorner MO, Scapagnini U (eds). Prolactin. Basic and Clinical Correlates Liviana Press: Padova 1985 833–847.
Carter JN et al. Prolactin-secreting tumors and hypogonadism in 22 men. New Engl J Med 1978 299, 847–852.
Chan-Tack KM. . Oral sildenafil in erectile dysfunction. Lancet 1998 352, 1557.
Acknowledgements
The assistance of Dr Michael J Raymond (Chief, Clinical Chemistry), and the financial support from the Queen's University Dean of Medicine, is gratefully acknowledged.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johri, A., Heaton, J. & Morales, A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 13, 176–182 (2001). https://doi.org/10.1038/sj.ijir.3900675
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900675
Keywords
This article is cited by
-
Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire
International Journal of Impotence Research (2023)
-
The Role of Hormones in Male Sexual Function
Current Sexual Health Reports (2020)
-
Androgens are Fundamental in the Maintenance of Male Sexual Health
Current Urology Reports (2011)
-
Hyperprolactinémie et fonction sexuelle chez l’homme
Andrologie (2005)
-
Psycho-biological correlates of hypoactive sexual desire in patients with erectile dysfunction
International Journal of Impotence Research (2004)